Nanoformulation of PROteolysis Targeting Chimera TArgeting ‘Undruggable’ C-Myc for The Treatment of Pancreatic Cancer A Saraswat, M Patki, Y Fu, S Barot, VV Dukhande, K Patel Nanomedicine 15 (18), 1761-1777, 2020 | 68 | 2020 |
Investigating the application of FDM 3D printing pattern in preparation of patient-tailored dosage forms PK Nukala, S Palekar, N Solanki, Y Fu, M Patki, AA Shohatee, ... Journal of 3D printing in medicine 3 (1), 23-37, 2019 | 59 | 2019 |
BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation D Rathod, Y Fu, K Patel European Journal of Pharmaceutical Sciences 138, 105039, 2019 | 56 | 2019 |
Folate receptor-targeted albumin nanoparticles based on microfluidic technology to deliver cabazitaxel F Meng, Y Sun, RJ Lee, G Wang, X Zheng, H Zhang, Y Fu, G Yan, Y Wang, ... Cancers 11 (10), 1571, 2019 | 41 | 2019 |
Process optimization of twin-screw melt granulation of fenofibrate using design of experiment (DoE) HK Mamidi, S Palekar, PK Nukala, SM Mishra, M Patki, Y Fu, P Supner, ... International Journal of Pharmaceutics 593, 120101, 2021 | 36 | 2021 |
β-cyclodextrin polymer/Soluplus® encapsulated Ebselen ternary complex (EβpolySol) as a potential therapy for vaginal candidiasis and pre-exposure prophylactic for HIV R Vartak, M Patki, S Menon, J Jablonski, S Mediouni, Y Fu, ST Valente, ... International Journal of Pharmaceutics 589, 119863, 2020 | 36 | 2020 |
Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing A Sarode, Y Fan, AE Byrnes, M Hammel, GL Hura, Y Fu, P Kou, C Hu, ... Nanoscale Advances 4 (9), 2107-2123, 2022 | 35 | 2022 |
Development of dual ARV-825 and nintedanib-loaded PEGylated nano-liposomes for synergistic efficacy in vemurafnib-resistant melanoma Y Fu, A Saraswat, Z Wei, MY Agrawal, VV Dukhande, SE Reznik, K Patel Pharmaceutics 13 (7), 1005, 2021 | 35 | 2021 |
Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma Y Fu, D Rathod, K Patel Experimental cell research 396 (1), 112275, 2020 | 29 | 2020 |
Multi-dose oral abuse deterrent formulation of loperamide using hot melt extrusion PK Nukala, S Palekar, M Patki, Y Fu, K Patel International journal of pharmaceutics 569, 118629, 2019 | 29 | 2019 |
M3814, a DNA-PK inhibitor, modulates ABCG2-mediated multidrug resistance in lung cancer cells ZX Wu, Z Peng, Y Yang, JQ Wang, QX Teng, ZN Lei, YG Fu, K Patel, L Liu, ... Frontiers in Oncology 10, 674, 2020 | 26 | 2020 |
Elevated ABCB1 expression confers acquired resistance to aurora kinase inhibitor GSK-1070916 in cancer cells ZX Wu, Y Yang, JQ Wang, WM Zhou, J Chen, YG Fu, K Patel, ZS Chen, ... Frontiers in pharmacology 11, 615824, 2021 | 24 | 2021 |
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma Y Fu, D Rathod, EM Abo-Ali, VV Dukhande, K Patel Pharmaceutics 11 (10), 504, 2019 | 23 | 2019 |
Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV M Patki, R Vartak, J Jablonski, S Mediouni, T Gandhi, Y Fu, E Cetindag, ... Colloids and Surfaces B: Biointerfaces 194, 111174, 2020 | 18 | 2020 |
Stromal disruption facilitating invasion of a ‘nano-arsenal’into the solid tumor Y Fu, AL Saraswat, J Monpara, K Patel Drug Discovery Today 27 (4), 1132-1141, 2022 | 15 | 2022 |
Overexpression of ABCB1 associated with the resistance to the KRAS-G12C specific inhibitor ARS-1620 in cancer cells XD Dong, M Zhang, CY Cai, QX Teng, JQ Wang, YG Fu, Q Cui, K Patel, ... Frontiers in Pharmacology 13, 843829, 2022 | 13 | 2022 |
Liposomal formulation: Opportunities, challenges, and industrial applicability Y Fu, A Saraswat, R Vartak, M Patki, K Patel Multifunctional Nanocarriers, 79-102, 2022 | 8 | 2022 |
Enhanced antisense oligonucleotide delivery using cationic liposomes incorporating fatty acid-modified polyethylenimine Z Guo, Y Li, Y Fu, T Guo, X Li, S Yang, J Xie Current Pharmaceutical Biotechnology 15 (9), 800-805, 2014 | 8 | 2014 |
Oral lipid nanocomplex of BRD4 PROteolysis TArgeting chimera and vemurafenib for drug-resistant malignant melanoma A Saraswat, R Vartak, R Hegazy, Y Fu, TJR Rao, B Billack, K Patel Biomedicine & Pharmacotherapy 168, 115754, 2023 | 5 | 2023 |
Microfluidic assembly of lipid nanoparticles for delivery of antisense oligonucleotides Y Zhou, Z Meng, T Guo, Y Fu, R J Lee, J Xie Current Pharmaceutical Biotechnology 15 (9), 823-828, 2014 | 3 | 2014 |